Black Diamond Therapeutics, Inc. (BDTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.83
- As of
Kresmion compiles this page from BDTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Black Diamond Therapeutics, Inc. (BDTX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
See the full BDTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BDTX on one page. Preview it with sample data, then open it live with a free account.
Preview the BDTX dossierActive events for BDTX
- high13F: large increase
CITADEL ADVISORS LLC added +72% to BDTX (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 57% of BDTX (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 14.7%, EPS $-0.17 vs $-0.1993 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 42.1% - EPS $-0.27 vs $-0.19 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 24.5% - EPS $-0.19 vs $-0.2516 estimate
FREE, NO ACCOUNT
Every event on BDTX, as it fires
You are seeing 5 of 8 events recorded on BDTX since 2026-06-12.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BDTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 09203E105 · 2026Q2 | $3.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 09203E105 · 2026Q2 | $291K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 09203E105 · 2026Q2 | $78K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BDTX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BDTX against its peers
BDTX's operating margin of 17.9% ranks in the 96th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | BDTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 70.0M USD | 7.9M USD | 82 | 13 |
| Operating margin | 17.9% | -326.6% | 96 | 11 |
| Net margin | 32.0% | -296.5% | 96 | 11 |
| Return on equity | 19.9% | -71.0% | 97 | 16 |
| P / E | 4.7x | n/a | n/a | 1 |
Peers (23): UNCY, PYPD, VYGR, BETRF, CBUS, NERV, VTVT, ENGN, NRXP, VANI, ANIX, OKUR, IMUX, VXRT, LENZ, TVGN, CLLS, FHTX, HUMA, ICCC, AVXL, NTHI, COYA. Left out: TLSA (period gap), RTSN (no annual filing). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (BDTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BDTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BDTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.